Kazandjian D (2016) Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol 43(6):676–681

Article  PubMed  PubMed Central  Google Scholar 

Goldschmidt H, Ashcroft J, Szabo Z, Garderet L (2019) Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Ann Hematol 98(1):1–18

Article  CAS  PubMed  Google Scholar 

van de Donk N, Usmani SZ (2018) CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol 9:2134

Article  PubMed  PubMed Central  Google Scholar 

Lee JH, Kim SH (2020) Treatment of relapsed and refractory multiple myeloma. Blood Res 55(S1):S43–S53

Article  PubMed  Google Scholar 

Hernandez-Rivas JA, Rios-Tamayo R, Encinas C, Alonso R, Lahuerta JJ (2022) The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res 10(1):1

Article  PubMed  PubMed Central  Google Scholar 

Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N (2006) Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery. Nature 443(7111):590–593

Article  CAS  PubMed  Google Scholar 

Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al (2010) Identification of a primary target of thalidomide teratogenicity. Science 327(5971):1345–1350

Article  CAS  PubMed  Google Scholar 

Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS et al (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343(6168):305–309

Article  CAS  PubMed  Google Scholar 

Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M et al (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343(6168):301–305

Article  PubMed  Google Scholar 

Jackson S, Xiong Y (2009) CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem Sci 34(11):562–570

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tao J, Yang J, Xu G (2018) The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners. Biochem Biophys Res Commun 507(1–4):443–449

Article  CAS  PubMed  Google Scholar 

Wang Y, Jiang X, Feng F, Liu W, Sun H (2020) Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B 10(2):207–238

Article  CAS  PubMed  Google Scholar 

Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S et al (2015) Drug Development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348(6241):1376–1381

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K et al (2015) Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol 22(6):755–763

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu G, Jiang X, Jaffrey SR (2013) A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition. J Biol Chem 288(41):29573–29585

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26(11):2326–2335

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gandhi AK, Mendy D, Waldman M, Chen G, Rychak E, Miller K et al (2014) Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol 164(2):233–244

Article  CAS  PubMed  Google Scholar 

Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118(18):4771–4779

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jian Y, Gao W, Geng C, Zhou H, Leng Y, Li Y et al (2017) Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. Oncol Lett 14(3):3243–3248

Article  PubMed  PubMed Central  Google Scholar 

Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132(12):1293–1303

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Song T, Zhou W, Xing L, Wang S, Ho M et al (2019) A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia 33(1):171–180

Article  PubMed  Google Scholar 

Zhou L, Yu W, Jayabalan DS, Niesvizky R, Jaffrey SR, Huang X et al (2020) Caspase-8 inhibition prevents the cleavage and degradation of E3 ligase substrate receptor cereblon and potentiates its biological function. Front Cell Dev Biol 8(1562):605989

Article  PubMed  PubMed Central  Google Scholar 

Zhou L, Huang X, Niesvizky R, Pu Z, Xu G (2021) Caspase-8 regulates the antimyeloma activity of bortezomib and lenalidomide. J Pharmacol Exp Ther 379(3):303–309

Article  CAS  PubMed  Google Scholar 

Duan Q, Li D, Xiong L, Chang Z, Xu G (2019) SILAC quantitative proteomics and biochemical analyses reveal a novel molecular mechanism by which ADAM12S promotes the proliferation, migration, and invasion of small cell lung cancer cells through upregulating hexokinase 1. J Proteome Res 18(7):2903–2914

Article  CAS  PubMed  Google Scholar 

Hu Z, Wang X, Li D, Cao L, Cui H, Xu G (2021) UFBP1, a key component in ufmylation, enhances drug sensitivity by promoting proteasomal degradation of oxidative stress-response transcription factor Nrf2. Oncogene 40(3):647–662

Article  CAS  PubMed  Google Scholar 

Chen D, Li Y-P, Yu Y-X, Zhou T, Liu C, Fei E-K et al (2018) Dendritic cell nuclear protein-1 regulates melatonin biosynthesis by binding to BMAL1 and inhibiting the transcription of N-acetyltransferase in C6 cells. Acta Pharmacol Sin 39(4):597–606

Article  CAS  PubMed  Google Scholar 

Liu G, Liu Q, Yan B, Zhu Z, Xu Y (2020) USP7 inhibition alleviates H2O2-induced injury in chondrocytes via inhibiting NOX4/NLRP3 pathway. Front Pharmacol 11(2480):617270

CAS  PubMed  Google Scholar 

Zhang Q-Q, Wang W-j, Li J, Yang N, Chen G, Wang Z et al (2015) Cathepsin L suppression increases the radiosensitivity of human glioma U251 cells via G2/M cell cycle arrest and DNA damage. Acta Pharmacol Sin 36(9):1113–1125

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen XH, Xu YJ, Wang XG, Lin P, Cao BY, Zeng YY et al (2019) Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis. Acta Pharmacol Sin 40(12):1568–1577

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hou X, Si J, Ren H, Ch